Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.

We profiled the expression of genes in benign and untreated human prostate cancer tissues using oligonucleotide microarrays. We report here 50 genes with distinct expression patterns in metastatic and confined tumors (Gleason score 6 and 9; lymph node invasive and noninvasive). Validation of expression profiles of 6 genes by quantitative PCR revealed a strong inverse correlation in the expression of zinc finger protein 185 (ZNF185), bullous pemphigoid antigen gene (BPAG1), and prostate secretory protein (PSP94) with progression of prostate cancer. Treatment of prostate cancer cell lines with 5-aza-2'-deoxycytidine (5-Aza-CdR), an inhibitor of DNA methylation, restored ZNF185 expression levels. Moreover, methylation-specific PCR confirmed methylation of the 5'CpG islands of the ZNF185 gene in all of the metastatic tissues and 44% of the localized tumor tissues, as well as in the prostate cancer cell lines tested. Thus, transcriptional silencing of ZNF185 by methylation in prostate tumor tissues implicates the ZNF185 gene in prostate tumorigenesis.

[1]  R. Cerione,et al.  Activation of the Ras-ERK Pathway Inhibits Retinoic Acid-induced Stimulation of Tissue Transglutaminase Expression in NIH3T3 Cells* , 2003, The Journal of Biological Chemistry.

[2]  V. Braga,et al.  Tumor progression: Small GTPases and loss of cell-cell adhesion. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[3]  W. Isaacs,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Pathological and Molecular Aspects of Prostate Cancer Prostate Cancer Ii , 2022 .

[4]  J. Licht,et al.  The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein* , 2002, The Journal of Biological Chemistry.

[5]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[6]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[7]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[8]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[9]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[10]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[11]  C. Der,et al.  Loss of Transgelin in Breast and Colon Tumors and in RIE-1 Cells by Ras Deregulation of Gene Expression through Raf-independent Pathways* , 2002, The Journal of Biological Chemistry.

[12]  Spyro Mousses,et al.  Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.

[13]  T. Rabbitts,et al.  The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target , 2002, Oncogene.

[14]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[15]  T. Stamey,et al.  Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.

[16]  G Rennert,et al.  Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. , 2001, The American journal of pathology.

[17]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[18]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[19]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[20]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[21]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[22]  I. Bach.  The LIM domain: regulation by association , 2000, Mechanisms of Development.

[23]  T. Koji,et al.  Prognostic significance of β‐microseminoprotein mRNA expression in prostate cancer , 1999 .

[24]  M. Haddad,et al.  Prostate secretory protein (PSP94) suppresses the growth of androgen‐independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis , 1999, The Prostate.

[25]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Klauck,et al.  Genomic structure of a novel LIM domain gene (ZNF185) in Xq28 and comparisons with the orthologous murine transcript. , 1997, Genomics.

[27]  C. Woodworth,et al.  Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines , 1997, Oncogene.

[28]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Robert,et al.  DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells , 2003, Nature Genetics.

[30]  Christoph Plass,et al.  Cancer epigenomics. , 2002, Human molecular genetics.

[31]  Y. Lo,et al.  New markers for cancer detection , 2002, Current oncology reports.

[32]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[33]  S. Weitzman,et al.  Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells. , 1995, The American journal of pathology.